Valopicitabine
Valopicitabine
Valopicitabine (pronunciation: /væloʊpɪsɪtəbiːn/) is an experimental antiviral drug that was under development for the treatment of hepatitis C.
Etymology
The name "Valopicitabine" is derived from the chemical structure of the drug. "Valo" refers to the valine moiety, "pici" refers to the picomolar potency, and "tabine" is a common suffix for antiviral drugs.
Pharmacology
Valopicitabine is a nucleoside analogue, which means it mimics the structure of nucleosides, the building blocks of DNA and RNA. It inhibits the replication of the hepatitis C virus by incorporating itself into the viral RNA and causing premature termination of the replication process.
Clinical Trials
Valopicitabine has undergone Phase II clinical trials for the treatment of hepatitis C. However, the development of the drug was discontinued due to adverse side effects, including gastrointestinal problems.
Related Terms
See Also
External links
- Medical encyclopedia article on Valopicitabine
- Wikipedia's article - Valopicitabine
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski